Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bullish +55

Bancreek Capital Management LP Acquires New Holdings in Boston ...

AI-generated analysis

πŸ“ˆ Bancreek Capital Management LP acquired 39,000 shares of Boston Scientific for approximately $2.45 million in Q1.

🏦 Multiple institutional investors including Frazier Financial Advisors and Mill Capital Management increased their stakes significantly.

πŸ’° The company reported revenue of $5.20 billion, surpassing analyst estimates by $10 million.

πŸ“Š Earnings per share reached $0.80, beating the consensus estimate of $0.79 for the quarter.

πŸš€ Boston Scientific authorized a new $5.00 billion stock repurchase program.

🎯 Q2 2026 EPS guidance is set between $0.82 and $0.84 per share.

πŸ“‰ Analyst price targets vary, with Raymond James at $88.00 and Leerink Partners at $74.00.

πŸ‘” Director Edward J. Ludwig purchased 3,580 shares worth approximately $203,000 in a single transaction.

πŸ“‰ Daiwa Securities Group downgraded the stock from 'strong-buy' to 'hold' recently.

πŸ“ˆ Revenue grew 11.6% compared to the same quarter last year.

Bullish Signals
  • Boston Scientific reported revenue of $5.20 billion, exceeding analyst consensus estimates by $10 million.
  • The company achieved earnings per share of $0.80, beating the expected $0.79 consensus.
  • Management authorized a new $5.00 billion stock repurchase plan, indicating confidence in undervaluation.
  • Revenue grew 11.6% year-over-year to $5.20 billion during the reported quarter.
  • Insiders have acquired over $980,000 worth of company stock in the last 90 days.
  • The firm maintains a strong balance sheet with a quick ratio of 1.22 and current ratio of 1.90.
Risk Factors
  • Daiwa Securities Group downgraded Boston Scientific from 'strong-buy' to 'hold' rating.
  • Raymond Financial lowered its price target from $97.00 to $88.00 on the stock.
  • Leerink Partners decreased its price objective from $87.00 to $74.00 despite maintaining an 'outperform' rating.
  • Wall Street Zen downgraded the stock from 'buy' to 'hold' in a recent report.
Full Analysis
Bancreek Capital Management LP increased its stake in Boston Scientific Corporation (NYSE: BSX) by purchasing 39,000 shares worth approximately $2.45 million during the first quarter, making the stock its sixth-largest holding at 10.6%. Several other institutional investors also adjusted their positions, with Frazier Financial Advisors boosting holdings by 56.3%, SouthState Bank increasing them by 4.0%, and Mill Capital Management raising its stake by 39.6% in the same period. Analyst sentiment regarding Boston Scientific remains mixed but generally positive, with an average rating of 'Moderate Buy' and a consensus price target of $79.84. Recent analyst actions include Daiwa Securities downgrading the stock to a 'hold', Raymond James lowering its price target to $88.00, and Leerink Partners reducing its objective to $74.00, while Piper Sandler maintained an 'overweight' rating with a $65.00 target. Financially, Boston Scientific reported strong quarterly results with revenue of $5.20 billion, beating estimates by $10 million, and earnings per share of $0.80 versus the consensus of $0.79. The company has set guidance for Q2 2026 EPS between $0.82 and $0.84 and full-year 2026 EPS between $3.34 and $3.41, with revenue growing 11.6% year-over-year. The company announced a new $5.00 billion stock repurchase authorization, signaling management's confidence in the stock's value. Insider activity was also notable, with Director Edward J. Ludwig purchasing 3,580 shares and Director Cheryl Pegus buying 1,770 shares, totaling over $980,000 in insider acquisitions within the last 90 days.